Travere Therapeutics, Inc. · NASDAQ:TVTX
Travere Therapeutics — Corporate Update (April 2026)
25 slides from Travere Therapeutics's corporate update, Apr 13, 2026
Slide 1: FILSPARI receives FDA approval for FSGS in patients without nephrotic syndrome
FILSPARI® (sparsentan) receives FDA approval for FSGS in patients without nephrotic syndrome April 13, 2026
Slide 2: Today's Speakers
Today’s Speakers Eric Dube, Ph.D. Jula Inrig, M.D. Peter Heerma President and Chief Executive Chief Medical Officer Chief Commercial Officer Officer
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including but not limited to statements about : statements regarding our products and products in development as potential foundational treatments and/or treatment standards; statements relating to the clinical studies
Slide 4: Living with FSGS meant constant hospitalizations
“Living with FSGS meant constant hospitalizations and missing out on a normal childhood, with no effective treatment options to rely on…The medications I was on often made me feel worse rather than better…” Madi enrolled in DUPLEX Trial at age 9 “After starting treatment in the clinical trial, for t
Slide 5: FILSPARI is the First and Only Medicine Approved for FSGS
FILSPARI is the First and Only Medicine Approved for FSGS; Expanding its Reach in Rare Kidney Conditions 1 2 3 4 Additional Indication Strong Clinical Profile in Execution-Ready Further Supports Expands Addressable FSGS Population without Commercial Platform Sustainable Growth Patient Population Nep
Slide 6: FSGS Represents Significant Patient and Community Burden
FSGS Represents Significant Patient and Community Burden Symptoms Side effects from of FSGS medications (IST) 7-year Fatigue 5-10 years kidney survival rate median time to for FSGS is the lowest | kidney failure for among primary High blood Significant toxicity 30-60% of glomerular diseases1 pressur
Slide 7: Proteinuria is the Primary Predictor of Disease Severity and Kidney Failure in FSGS
Proteinuria is the Primary Predictor of Disease Severity and Kidney Failure in FSGS Role of Elevated and Persistent Proteinuria in FSGS PROTEINURIA Podocyte Podocyte Glomerular Glomerular Tubulointerstitial injury1,2 Loss3,4,5 hypertrophy sclerosis1,2 fibrosis1,2 hyperfiltration6,7 KIDNEY FAILURE Ab
Slide 8: All Types of FSGS Share a Similar Glomerular Lesion Initiated by Podocyte Injury
Regardless of the Underlying Etiology, All Types of FSGS Share a Similar Glomerular Lesion Initiated by Podocyte Injury PRIMARY GENETIC UNDETERMINED CAUSE SECONDARY FSGS lesions with diffuse foot Identified genetic variants of FSGS lesions without diffuse Secondary to other disease process effacemen
Slide 9: Broad Patient Population Defined by Absence of Nephrotic Syndrome
Broad Patient Population Defined by Absence of Nephrotic Syndrome FSGS without Nephrotic Syndrome FSGS with Nephrotic Syndrome* DIAGNOSTIC CHARACTERISTICS DIAGNOSTIC CHARACTERISTICS (concurrently meeting all criteria) • Absence of one or more of the nephrotic • Proteinuria >3.5 g/24h2 syndrome crite
Slide 10: In DUPLEX, Even Greater Reduction in Proteinuria in FSGS without Nephrotic Syndrome
In DUPLEX, Treatment with FILSPARI Demonstrated Even Greater Reduction in Proteinuria in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* Overall DUPLEX Population % reduction in UPCR from baseline by visit % reduction in UPCR from baseline by visit 0% 0% LS Mean Change
Slide 11: Even Greater Relative Proteinuria Reduction Across Thresholds
In DUPLEX, FILSPARI Demonstrated Even Greater Relative Proteinuria Reduction Across Thresholds in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* Overall DUPLEX Population Patients achieving UPCR thresholds1, % Patients achieving UPCR thresholds1,2, % FILSPARI (N=129) I
Slide 12: Clinically Meaningful Effect on eGFR
In DUPLEX, FILSPARI Demonstrated a Clinically Meaningful Effect on eGFR in FSGS without Nephrotic Syndrome DUPLEX Population without Nephrotic Syndrome* FILSPARI Irbesartan Difference p-value5 (N=129)1 (N=125)1 Adjusted Mean Change in eGFR (mL/min/1.73 m2) at Week 108 -11.3 -12.4 1.1 NS from baselin
Slide 13: Even Stronger Benefit on Exploratory Kidney Outcome Endpoints
In DUPLEX, FILSPARI Demonstrated Even Stronger Benefit on Exploratory Kidney Outcome Endpoints in FSGS without Nephrotic Syndrome FILSPARI showed clinically meaningful benefit in the broad DUPLEX population, with enhanced efficacy in population without nephrotic syndrome* 14 FILSPARI Irbesartan RR:
Slide 14: Long-Term Safety and Tolerability Consistent with IgAN Profile
Long-Term Safety and Tolerability Consistent with IgAN Profile Adverse reactions reported in 2% or more of subjects with FSGS treated with FILSPARI (overall DUPLEX population) FILSPARI Irbesartan Adverse Reactions, % (N=184) (N=187) Peripheral edema1 42 (23) 45 (24) Hypotension (including orthostati
Slide 15: FILSPARI: The First and Only FDA-Approved Medicine for FSGS
FILSPARI: The First and Only FDA-Approved Medicine for FSGS Overview of Prescribing Information FILSPARI is indicated to reduce proteinuria in adult and Indication pediatric patients aged 8 years and older with focal Statement segmental glomerulosclerosis (FSGS) without nephrotic syndrome Adults and
Slide 16: Launch Readiness and Adoption Drivers Support Significant FSGS Opportunity
Launch Readiness and Adoption Drivers Support Significant FSGS Opportunity FSGS has a significant unmet need with high The first and only FDA-approved medicine indicated for FSGS urgency to treat Highly severe and fast progressing disease with ~75% of >30k addressable surveyed nephrologists indicati
Slide 17: KDIGO Guidelines Recommend FSGS Management Based on Nephrotic Syndrome Status
KDIGO Guidelines Recommend FSGS Management Based on Nephrotic Syndrome Status Patient with FSGS lesion on kidney biopsy Presence of nephrotic syndrome Absence of nephrotic syndrome Nephrotic-range proteinuria >3.5 g/d Proteinuria >3.5 g/d BUT AND Serum albumin >3.0 g/dl Serum albumin <3.0 g/dl with
Slide 18: >30K patients addressable at launch
Addressable FSGS Population Across Disease Subtypes is Expected to Grow Over Time >30,000 addressable patients with clear drivers of future growth Future growth drivers: Population growth >30K patients addressable at launch Earlier referral to Secondary and nephrologist in light of Undetermined Caus
Slide 19: Proven IgAN Launch Execution Positions FILSPARI for a Successful Launch in FSGS
Proven IgAN Launch Execution Positions FILSPARI for a Successful Launch in FSGS Benchmark Setting Rare FILSPARI’s launch in IgAN has significantly outperformed Disease Launch Executed benchmark rare renal launches over the past five years1 by Premier Commercial Quarterly Net Product Sales Infrastruc
Slide 20: Leveraging Existing Infrastructure to Support Successful Launch in FSGS
Leveraging Existing Infrastructure to Support Successful Launch in FSGS ~7,000 • Target physicians that manage patients with IgAN and FSGS Expanding target >80% • Prescriber overlap between IgAN and FSGS physician universe to drive further synergies between 100+ IgAN and FSGS launches • Established
Slide 21: Strong Anticipation and Clinical Familiarity with FILSPARI to Drive Utilization
Strong Anticipation and Clinical Familiarity with FILSPARI to Drive Utilization Among nephrologists, FILSPARI is the most familiar FSGS pipeline agent today1 84% of nephrologists indicate novel non-immunosuppressives are highly desirable in FSGS1 ~70% of nephrologists are “extremely familiar” with F
Slide 22: Execution-Ready Commercial Organization for FSGS Launch
Execution-Ready Commercial Organization for FSGS Launch Patient & Strong Commercial Access & Comprehensive Product Available Physician Focus Foundation Reimbursement Support Program Day 1 Continuous patient Experienced field Established payer Travere TotalCare Streamlined logistics and physician tea
Slide 23: Travere TotalCare: Support for Patients Prescribed FILSPARI for IgAN and FSGS
Travere TotalCare: Support for Patients Prescribed FILSPARI for IgAN and FSGS Dedicated personal support from Travere TotalCare nurse educators Services and programs designed to help patients start and stay compliant on FILSPARI Connect patients with financial support options FILSPARI available for
Slide 24: Strategic Priorities to Drive Significant Growth Now and in the Future
Strategic Priorities to Drive Significant Growth Now and in the Future Reinforce FILSPARI’s foundational position in a growing IgAN market Successfully launch FILSPARI in FSGS Successful enrollment in Phase 3 HARMONY Study to position pegtibatinase as the first potential disease-modifying therapy fo
Slide 25: Inc.
© 2026 2025 Travere Therapeutics, Inc. Inc.